Influence of ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction.
作者信息
Bajaj Navkaranbir S, Claggett Brian, Lewis Eldrin F, Desai Akshay S, Fang James C, O'Meara Eileen, Shah Sanjiv J, Sweitzer Nancy K, Fleg Jerome L, Pitt Bertram, Rouleau Jean L, Finn Peter, Pfeffer Marc A, Solomon Scott D
机构信息
Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
University of Utah School of Medicine, Salt Lake City, UT, USA.
出版信息
Eur J Heart Fail. 2018 Apr;20(4):815-816. doi: 10.1002/ejhf.1040. Epub 2017 Oct 25.
Abstract
摘要
相似文献
1
Influence of ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction.射血分数对射血分数保留的心力衰竭患者特定病因死亡率的影响。
Eur J Heart Fail. 2018 Apr;20(4):815-816. doi: 10.1002/ejhf.1040. Epub 2017 Oct 25.
2
Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction.射血分数保留的心力衰竭患者的心率与不良结局风险
Eur J Prev Cardiol. 2017 Jul;24(11):1212-1219. doi: 10.1177/2047487317708676. Epub 2017 May 9.
3
Recovered heart failure with reduced ejection fraction and outcomes: a prospective study.射血分数降低的心力衰竭的恢复和结局：一项前瞻性研究。
Eur J Heart Fail. 2017 Dec;19(12):1615-1623. doi: 10.1002/ejhf.824. Epub 2017 Apr 6.
4
Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response.射血分数保留的心力衰竭患者亚组特征及其对预后和治疗反应的潜在影响
Eur J Heart Fail. 2015 Sep;17(9):925-35. doi: 10.1002/ejhf.327. Epub 2015 Aug 6.
5
The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction).射血分数保留的心力衰竭患者的住院负担和住院后死亡率风险：I-PRESERVE 试验（伊贝沙坦治疗心力衰竭和保留射血分数）的结果。
JACC Heart Fail. 2015 Jun;3(6):429-441. doi: 10.1016/j.jchf.2014.12.017. Epub 2015 May 14.
6
A comprehensive population-based characterization of heart failure with mid-range ejection fraction.具有中等范围射血分数的心力衰竭的综合人群特征描述。
Eur J Heart Fail. 2017 Dec;19(12):1624-1634. doi: 10.1002/ejhf.945. Epub 2017 Sep 25.
7
Prognostic Factors After Index Hospitalization for Heart Failure With Preserved Ejection Fraction.射血分数保留的心力衰竭患者首次住院后的预后因素
Am J Cardiol. 2017 Jun 15;119(12):2017-2020. doi: 10.1016/j.amjcard.2017.03.032. Epub 2017 Mar 30.
8
Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Heart Failure Network).急性心力衰竭患者射血分数与充血指标的轨迹（来自心力衰竭网络）
Am J Cardiol. 2017 Jul 1;120(1):98-105. doi: 10.1016/j.amjcard.2017.03.249. Epub 2017 Apr 12.
9
Association Between Use of Statins and Mortality in Patients With Heart Failure and Ejection Fraction of ≥50.射血分数≥50%的心力衰竭患者使用他汀类药物与死亡率之间的关联
Circ Heart Fail. 2015 Sep;8(5):862-70. doi: 10.1161/CIRCHEARTFAILURE.115.002143. Epub 2015 Aug 4.
10
Comparison of Risk of Re-hospitalization, All-Cause Mortality, and Medical Care Resource Utilization in Patients With Heart Failure and Preserved Versus Reduced Ejection Fraction.射血分数保留与降低的心力衰竭患者再住院风险、全因死亡率及医疗资源利用情况的比较
Am J Cardiol. 2015 Oct 1;116(7):1088-92. doi: 10.1016/j.amjcard.2015.07.018. Epub 2015 Jul 15.
引用本文的文献
1
Extended-Release Oral Milrinone for the Treatment of Heart Failure With Preserved Ejection Fraction.延长释放型口服米力农治疗射血分数保留的心力衰竭。
J Am Heart Assoc. 2020 Jul 7;9(13):e015026. doi: 10.1161/JAHA.119.015026. Epub 2020 Jun 18.
2
Noncardiac comorbidity clustering in heart failure: an overlooked aspect with potential therapeutic door.心力衰竭中的非心脏合并症聚集：一个被忽视的具有潜在治疗意义的方面。
Heart Fail Rev. 2022 May;27(3):767-778. doi: 10.1007/s10741-020-09972-6.
3
Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial).射血分数降低的心力衰竭住院后猝死（来自EVEREST试验）
Am J Cardiol. 2018 Jul 15;122(2):255-260. doi: 10.1016/j.amjcard.2018.03.362. Epub 2018 Apr 11.
本文引用的文献
1
Spironolactone Metabolites in TOPCAT - New Insights into Regional Variation.TOPCAT研究中的螺内酯代谢物——区域差异的新见解
N Engl J Med. 2017 Apr 27;376(17):1690-1692. doi: 10.1056/NEJMc1612601.
2
Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction.射血分数对射血分数保留的心力衰竭患者使用螺内酯的疗效及预后的影响。
Eur Heart J. 2016 Feb 1;37(5):455-62. doi: 10.1093/eurheartj/ehv464. Epub 2015 Sep 15.
3
Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.TOPCAT 试验中醛固酮拮抗剂治疗心脏收缩功能保留心力衰竭患者及结局的地域差异。
Circulation. 2015 Jan 6;131(1):34-42. doi: 10.1161/CIRCULATIONAHA.114.013255. Epub 2014 Nov 18.
4
Developing therapies for heart failure with preserved ejection fraction: current state and future directions.射血分数保留的心力衰竭治疗方法：现状与未来方向
JACC Heart Fail. 2014 Apr;2(2):97-112. doi: 10.1016/j.jchf.2013.10.006.
5
Spironolactone for heart failure with preserved ejection fraction.螺内酯治疗射血分数保留的心力衰竭。
N Engl J Med. 2014 Apr 10;370(15):1383-92. doi: 10.1056/NEJMoa1313731.
6
Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction.治疗保留心功能心力衰竭伴醛固酮拮抗剂试验的原理和设计：螺内酯治疗有症状心力衰竭和射血分数保留患者的随机对照研究。
Am Heart J. 2011 Dec;162(6):966-972.e10. doi: 10.1016/j.ahj.2011.09.007. Epub 2011 Nov 8.
7
Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients.射血分数对广泛心力衰竭患者心血管结局的影响。
Circulation. 2005 Dec 13;112(24):3738-44. doi: 10.1161/CIRCULATIONAHA.105.561423. Epub 2005 Dec 5.
Zotero 插件